Vascular endothelial growth factor in tumor cells in platinum-containing chemotherapy of advanced ovarian cancer


Aim. Study of the relationship of vascular endothelial growth factor expression in tumor cells of ascites and primary tumor in patients with ascitic form of ovarian cancer undergoing neoadjuvant chemotherapy according to the AP scheme (doxorubicin + cisplatin).

Methods. The level of vascular endothelial growth factor messenger ribonucleic acid (mRNA) was assessed using PCR-RT in epithelial cells of ascites and primary tumor tissue obtained intraoperatively after 2–4 courses of neoadjuvant chemotherapy according to the AP scheme from 25 patients with a verified diagnosis of ovarian cancer (serous adenocarcinoma) at stage III–IV according to the International Federation of Gynecology and Obstetrics. Processing of the results was performed using the software package Statistica 10.

Results. An increase in the expression of vascular endothelial growth factor mRNA in epithelial cells of ascites in 60% of samples was established. In the intraoperatively obtained tumor tissue after 2–4 courses of neoadjuvant chemotherapy according to the AP scheme, vascular endothelial growth factor expression was increased in 73% of the samples. At the same time, the increase of relative expression in the tumor after neoadjuvant chemotherapy did not depend on the degree of therapeutic pathomorphosis but was related to early relapse and increased level of cancer antigen-125 (CA-125). Median of relapse-free survival in vascular endothelial growth factor-positive ovarian cancer was less than 5 months.

Conclusion. Neoadjuvant chemotherapy according to the AP scheme increases the expression of vascular endothelial growth factor in the tumor tissue in advanced ovarian cancer; the degree of vascular endothelial growth factor overexpression in ovarian tumor is related to the presence of early relapse and an increase in the serum CA-125 level.

S O Gening

Ulyanovsk State University

Ulyanovsk, Russia

D R Dolgova

Ulyanovsk State University

Ulyanovsk, Russia

I I Antoneeva

Ulyanovsk State University; Regional Clinical Oncological Dispensary

Ulyanovsk, Russia; Ulyanovsk, Russia

T V Abakumova

Ulyanovsk State University

Ulyanovsk, Russia

I O Kolodiy

Ulyanovsk State University

Ulyanovsk, Russia

T P Gening

Ulyanovsk State University

Author for correspondence.
Ulyanovsk, Russia

  1. Kaprin A.D., Starinskiy V.V., Petrova G.V. Sostojanie onkologicheskoj pomoshhi naseleniju Rossiiv 2017 godu. (The state of cancer care for the population of Russia in 2017.) Moscow: Moscow Research Institute of Oncology named P.A. Herzenbranch of the Federal State Budgetary Institution “National Medical Research Center of Radiology” of the Ministry of Health of Russia. 2018; 236 p. (In Russ).
  2. Cooke S.L., Brenton J.D. Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol. 2011; 12 (12): 1169–1174. doi: 10.1016/S1470-2045(11)70123-1.
  3. Tiper I.V., Temkin S.M., Spiegel S. et al. VEGF Potentiates GD3-mediated immunosuppression by human ovarian cancer cells. Clin. Cancer Res. 2016; 22 (16): ­4249–4258. doi: 10.1158/1078-0432.CCR-15-2518.
  4. Yaqoob U., Cao S., Shergill U. et al. Neuropilin-1 stimulates tumor growth by increasing fibronectin fibril assembly in the tumor microenvironment. Cancer Res. 2012; 72 (16): 4047–4059. doi: 10.1158/0008-5472.CAN-11-3907.
  5. Zhang L., Wang H., Li C. et al. VEGF-A/neuropi­lin 1 pathway confers cancer stemness via activating Wnt/β-ca­tenin axis in breast cancer cells. Cell Physiol. Biochem. 2017; 44 (3): 1251–1262. doi: 10.1159/000485455.
  6. Jang K., Kim M., Gilbert C.A. et al. VEGFA activates an epigenetic pathway upregulating ovarian cancer-initiating cells. EMBO Mol. Med. 2017; 9 (3): 304–318. doi: 10.15252/emmm.201606840.
  7. Hemachandra L.P., Shin D.H., Dier U. et al. Mitochondrial superoxide dismutase has a protumorigenic role in ovarian clear cell carcinoma. Cancer Res. 2015; 75 (22): 4973–4984. doi: 10.1158/0008-5472.CAN-14-3799.
  8. Hata K., Watanabe Y., Nakai H. et al. Expression of the vascular endothelial growth factor (VEGF) gene in epi­thelial ovarian cancer: an approach to anti-VEGF therapy. Anticancer Res. 2011; 31 (2): 731–737. PMID: 21378364.
  9. Kit O.I., Frantsiyants E.M., Moiseenko T.I. et al. Some growth factors of vegf and fgf-21 families in the ascitic fluid and blood serum in the dynamics of ovarian cancer development. Zdorov'e i obrazovanie v XXI veke. 2016; 18 (4): 15–21. (In Russ).
  10. Gershteyn E.S., Kushlinskiy D.N., Tereshkina I.V. et al. Vascular Endothelial Growth Factor And The Tumors Of Female Reproductive System. Part II. Ovarian Cancer And Endometrial Cancer. Onkoginekologiya. 2015; (2): 4–11. (In Russ.)
  11. Yu L., Deng L., Li J. et al. The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis. Gynecol. Oncol. 2013; 128 (2): 391–396. doi: 10.1016/j.ygyno.2012.11.002.
  12. Böhm S., Faruqi A., Said I. et al. Chemotherapy response score: Development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J. Clin. Oncol. 2015; 33: 2457–2463. doi: 10.1200/JCO.2014.60.5212.
  13. Villert A.B., Kolomiets L.A., Yunusova N.V., Ivanova A.A. Ascites as a subject of studies in ovarian cancer. Sibirskiy onkologicheskiy zhurnal. 2019; 18 (1): 116–123. (In Russ.)
  14. Ahmed N., Thompson E.W., Quinn M.A. Epithe­lial-mesenchimal interconversions in normal ovarian surface epi­thelium and ovarian carcinomas: an expection to the norm. J.Cell. Phisiol. 2007; 213 (3): 581–588. doi: 10.1002/jcp.21240.
  15. Ho C.M., Chang S.F., Hsiao C.C. et al. Isolation and characterization of stromal progenitor cells from ascites of patients with epithelial ovarian adenocarcinoma. J. Biomed. Sci. 2012; 14: 19–23. doi: 10.1186/1423-0127-19-23.


Abstract - 21

PDF (Russian) - 25



© 2019 Gening S.O., Dolgova D.R., Antoneeva I.I., Abakumova T.V., Kolodiy I.O., Gening T.P.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Свидетельство о регистрации СМИ ЭЛ № ФС 77-75008 от 1 февраля 2019 года выдано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор)